Volume | 5,035 |
|
|||||
News | - | ||||||
Day High | 1.76 | Low High |
|||||
Day Low | 1.7316 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ARCA Biopharma Inc | ABIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.76 | 1.7316 | 1.76 | 1.75 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
136 | 5,035 | $ 1.75 | $ 8,833 | - | 1.56 - 2.16 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:52:53 | 300 | $ 1.75 | USD |
ARCA Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
25.38M | 14.50M | - | 0 | -5.34M | -0.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ARCA Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.76 | 1.80 | 1.69 | 1.75 | 27,594 | -0.01 | -0.57% |
1 Month | 1.65 | 1.80 | 1.58 | 1.70 | 27,841 | 0.10 | 6.06% |
3 Months | 1.64 | 1.80 | 1.56 | 1.66 | 26,830 | 0.11 | 6.71% |
6 Months | 2.01 | 2.06 | 1.56 | 1.76 | 25,223 | -0.26 | -12.94% |
1 Year | 2.04 | 2.16 | 1.56 | 1.90 | 24,321 | -0.29 | -14.22% |
3 Years | 3.69 | 3.90 | 1.56 | 2.74 | 119,628 | -1.94 | -52.57% |
5 Years | 0.3751 | 22.00 | 0.29 | 8.12 | 330,631 | 1.37 | 366.54% |
ARCA Biopharma Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |